← Back to All Filings

ResMed Director Files Form 144 for $227K Proposed Share Sale

Low SignificanceSeptember 2, 2026 at 7:35:45 PM EDT

RESMED INC

$RMD144CIK: 0000943819

Subscribe to track RMD

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

📋 Form 144 Proposed Sale Notice Company: ResMed INC ($RMD) Insider: Peter C Farrell (Director) Shares to Sell: 970 Common Shares Estimated Value: $227,608.41 (~$234.65/share) Approx. Sale Date: 09/02/2026 Trading Plan: Rule 10b5-1 (Adopted 08/12/2025) Broker: Merrill Lynch

Comprehensive Analysis

Executive Summary

On September 2, 2026, Peter C Farrell, Director at ResMed INC ($RMD), filed a Form 144 notice proposing the sale of 970 shares of common stock through Merrill Lynch, with an estimated aggregate market value of $227,608.41 ($234.65 per share).

Key Filing Details

  • Insider: Peter C Farrell
  • Title/Role: Director
  • Securities Offered: 970 Common shares
  • Aggregate Market Value: $227,608.41
  • Origin of Shares: Acquired via Stock Option exercise on November 11, 2015
  • Trading Plan: Pre-arranged Rule 10b5-1 trading plan adopted on August 12, 2025
  • Recent Prior Sales: 8,000 shares sold on August 5, 2026, for gross proceeds of $1,799,642.92
  • Shares Outstanding: 144,252,306 shares

Impact Analysis

The proposed transaction represents less than 0.001% of ResMed's outstanding common stock and is executed pursuant to a pre-established Rule 10b5-1 trading plan. Given the small transaction size and routine nature of the sale under a 10b5-1 plan, market impact is expected to be negligible.

Topics:#ResMed#RMD#InsiderTrading#Form144#SEC

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.